Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome

NCT04401748 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

531

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelodysplastic Syndrome (MDS)

Interventions

DRUG: Venetoclax
DRUG: Azacitidine
DRUG: Placebo

Sponsor

AbbVie

Collaborators

Genentech, Inc.